To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts
NCT ID:
NCT05520658
Condition:
Plantar Wart
Conditions: Official terms:
Warts
Foot Diseases
Fluorouracil
Digoxin
Furosemide
Study type:
Interventional
Study phase:
N/A
Overall status:
Unknown status
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
combined digoxin and furosemide
Description:
one session every 2 weeks for maximum 6 sessions
Arm group label:
group A
Intervention type:
Drug
Intervention name:
5 fluorouracil
Description:
5 fluorouracil mixed with1ml of 2% lignocaine and epinephrine one session every 2 weeks
for maximum 6 sessions .
Arm group label:
group B
Summary:
Warts are common skin infections caused by human papillomavirus (HPV), which can cause a
variety of skin presentations according to its type, site and the immune status
.Nongenital warts may be presented as common, plane, plantar, filiform, or mucosal warts
.Most people are affected by cutaneous warts, either plantar warts or common warts
.prevalence of skin warts is between 3% and 13% and plantar warts are about 30% of skin
warts in western world .Majority of cases occur in adolescent and young adults
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Age:>18 years .
- Sex: both males and females will be included.
- Confirmed diagnosis by clinical and dermoscopic examination of plantar warts will be
made
Exclusion Criteria:
- Patients with history or evidenced hypersensitivity to any component used in this
study.
- Pregnancy & lactating.
- Patients who receive immune suppressive therapy.
- Patients who receive any wart treatment during the last 2 months before enrollment
in the study.
- Patients with systemic illness especially cardiac patients.
- Patients who refused participation in the study
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Sohag University Hospital
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Osama R Elshrif, professor
Start date:
July 1, 2022
Completion date:
September 2022
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05520658